Esreboxetine
Chemical compound / From Wikipedia, the free encyclopedia
Esreboxetine (developmental code names AXS-14, PNU-165442G) is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.[1][2][3][4] It is the (S,S)-(+)-enantiomer of reboxetine and is even more selective as a norepinephrine reuptake inhibitor in comparison.[1][5]
Quick Facts Clinical data, Other names ...
Clinical data | |
---|---|
Other names | AXS-14; PNU-165442G |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG |
|
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H23NO3 |
Molar mass | 313.397 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
However, recently it has been found that esreboxetine could be effective in fibromyalgia patients.[6]